- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Epclusa is a pan genotype antiviral drug for hepatitis C, but it is not suitable for all patients. Severe liver injury patients may have an inc...
Jisanda is a commonly used medication for the treatment of chronic hepatitis C. Some patients may experience headaches, fatigue, or nausea duri...
Baricitinib is an oral JAK inhibitor used to treat autoimmune diseases. Standardized medication is the key to ensuring efficacy and safety, and...
Baricitinib is a JAK inhibitor, and when treating inflammatory diseases, special attention should be paid to risks such as infection, thrombosi...
Baricitinib is a JAK inhibitor with clear contraindications for use in specific patient populations. The following three groups of people need ...
Baricitinib may cause side effects such as upper respiratory tract infections, nausea, and headaches during treatment. Scientific management of...
Regorafenib is an oral multi-target inhibitor, and its efficacy relies on precise dosage execution and rigorous adverse event monitoring. The f...
The medication safety of regorafenib relies on active monitoring and immediate intervention of the three core adverse reactions. The following ...
Regorafenib has a clear use of the "red line". The following two groups of people belong to the category of absolute or relative contraindicati...
Targeted drug regorafenib often accompanies adverse reactions in treatment, among which fatigue, stomatitis, and decreased appetite have the gr...
